References
- HasselströmJLiu-PalmgrenJRasjö-WrååkGPrevalence of pain in general practiceEur J Pain20026537538512160512
- ZhangWMoskowitzRWNukiGOARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidenceOsteoarthritis Cartilage2007159981100017719803
- ZhangWMoskowitzRWNukiGOARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis Cartilage200816213716218279766
- WeaverALCurrent and emerging treatments for mild/moderate acute ambulatory painAm J Ther200815Suppl 10S12S1619127123
- FendrickAMGreenbergBPA review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritisOsteopath Med Prim Care20093119126235
- HuntRHHarperSWatsonDJThe gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal eventsAm J Gastroenterol20039881725173312907325
- BardouMBarkunANPreventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor interventionJoint Bone Spine201077161220022539
- LanasASopeñaFNonsteroidal anti-inflammatory drugs and lower gastrointestinal complicationsGastroenterol Clin North Am200938233335219446262
- AlacquaMTrifiròGCavagnaLPrescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawalArthritis Rheum200859456857418383398
- BarozziNTettSEWhat happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?Pharmacoepidemiol Drug Saf200716111184119117636557
- GreenbergJDFisherMCKremerJThe COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular riskClin Exp Rheumatol200927339540119604430
- DrummondMFerrazMBMasonJAssessing the cost effectiveness of NSAID: an international perspectiveJ Rheumatol1995227140814117562786
- MäntyselkäPAhonenRKumpusaloETakalaJVariability in prescribing for musculoskeletal pain in Finnish primary health carePharm World Sci200123623223611826513
- Caudill-SlosbergMASchwartzLMWoloshinSOffice visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000Pain2004109351451915157714
- HoltedahlRAnalgesics use in patients with chronic musculoskeletal complaintsTidsskr Nor Laegeforen2004124151930193215306862
- MäntyselkäPAhonenRViinamäkiHTakalaJKumpusaloEDrug use by patients visiting primary care physicians due to nonacute musculoskeletal painEur J Pharm Sci2002174–520120612453609
- WilsonRDAnalgesic prescribing for musculoskeletal complaints in the ambulatory care setting after the introduction and withdrawal of cyclooxygenase-2 inhibitorsArch Phys Med Rehabil20099041147115119577028
- FosbølELGislasonGHJacobsenSThe pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million peoplePharmacoepidemiol Drug Saf200817882283318383428
- SchnitzerTJUpdate on guidelines for the treatment of chronic musculoskeletal painClin Rheumatol200625Suppl 1S22S2916741783
- PatrignaniPTacconelliSCaponeMLRisk management profile of etoricoxib: an example of personalized medicineTher Clin Risk Manag20084598399719209280
- HurCChanATTramontanoACGazelleGSCoxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costsAnn Pharmacother20064061052106316720709
- CombeBSwergoldGMcLayJCardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)Rheumatology200948442543219223284
- FarkouhMEGreenbergBPAn evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugsAm J Cardiol20091031227123719406264